Abstract
Abstract Introduction: Fosfomycin has a unique structure and mechanism of action among antimicrobials. It has reemerged as a potential tool against multidrug-resistant organisms in intensive care units. In this study, we looked into the clinical outcomes of patients treated with intravenous fosfomycin in our center for the past 5 years. Materials and Methods: A retrospective observational study on the characteristics and clinical outcomes of patients who received fosfomycin as definitive therapy from 2016 to 2021 was done. Results: The indications for use of fosfomycin were urosepsis (34%), intra-abdominal infections (22%), and primary bacteremia. The overall cure rate on treatment with fosfomycin was 69%. The highest cure rate was seen with meningitis, urosepsis, and skin and soft-tissue infections (SSTIs). Patients with infections caused by Escherichia coli had better survival than others. Adverse events were seen only in 6%. Conclusions: Fosfomycin is a very effective drug for urinary tract infections, SSTIs, and meningitis caused by carbapenem-resistant E. coli.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
